Shares of Affimed N.V. (NASDAQ:AFMD) have been assigned a consensus recommendation of “Hold” from the six ratings firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $5.38.

AFMD has been the subject of several research analyst reports. ValuEngine upgraded shares of Affimed N.V. from a “strong sell” rating to a “sell” rating in a research report on Friday, June 30th. Oppenheimer Holdings, Inc. set a $10.00 price target on shares of Affimed N.V. and gave the stock a “buy” rating in a research note on Thursday, May 18th. Jefferies Group LLC restated a “hold” rating and set a $2.50 price target on shares of Affimed N.V. in a research note on Thursday, July 27th. Finally, SunTrust Banks, Inc. started coverage on shares of Affimed N.V. in a research note on Thursday, July 13th. They set a “buy” rating and a $7.00 price target on the stock.

ILLEGAL ACTIVITY WARNING: “Affimed N.V. (AFMD) Receives Average Rating of “Hold” from Brokerages” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/affimed-n-v-afmd-receives-average-rating-of-hold-from-brokerages/1535116.html.

Institutional investors have recently made changes to their positions in the company. Creative Planning increased its position in shares of Affimed N.V. by 30.0% in the first quarter. Creative Planning now owns 65,000 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 15,000 shares in the last quarter. Nationwide Fund Advisors boosted its position in shares of Affimed N.V. by 9,542.0% in the first quarter. Nationwide Fund Advisors now owns 484,027 shares of the biopharmaceutical company’s stock worth $1,113,000 after buying an additional 479,007 shares in the last quarter. NEA Management Company LLC purchased a new position in shares of Affimed N.V. during the first quarter worth about $8,944,000. Wellington Management Group LLP boosted its position in shares of Affimed N.V. by 30.8% in the first quarter. Wellington Management Group LLP now owns 5,413,291 shares of the biopharmaceutical company’s stock worth $12,450,000 after buying an additional 1,274,852 shares in the last quarter. Finally, Tekla Capital Management LLC boosted its position in shares of Affimed N.V. by 377.7% in the first quarter. Tekla Capital Management LLC now owns 1,405,324 shares of the biopharmaceutical company’s stock worth $3,232,000 after buying an additional 1,111,111 shares in the last quarter. 42.34% of the stock is owned by institutional investors.

Shares of Affimed N.V. (AFMD) opened at 1.9875 on Friday. Affimed N.V. has a 52-week low of $1.65 and a 52-week high of $3.20. The stock’s 50 day moving average is $2.15 and its 200-day moving average is $2.24. The firm’s market capitalization is $87.33 million.

Affimed N.V. (NASDAQ:AFMD) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.02. The firm had revenue of $0.51 million during the quarter, compared to analysts’ expectations of $1.31 million. Affimed N.V. had a negative net margin of 978.31% and a negative return on equity of 73.85%. The firm’s revenue for the quarter was down 75.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.24) earnings per share. On average, equities analysts forecast that Affimed N.V. will post ($0.84) earnings per share for the current fiscal year.

Affimed N.V. Company Profile

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Receive News & Ratings for Affimed N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.